Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective

In this Immunotherapy perspective, learn more about advances and possible future developments in adoptive immunotherapy.

Go to the profile of RegMedNet
Aug 03, 2018
0
0

Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma's investment in the field of T-cell therapeutics. In this perspective from Immunotherapy, Chungyong Han and Byoung S Kwon discuss advances in adoptive immunotherapy and review CAR T-cell studies that focus on CAR constructs, target antigens and T-cell phenotypes.

Han C, Kwon BS. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Immunotherapy. 10(3), 221–234 (2018)

Go to the profile of RegMedNet

RegMedNet

eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.